Abstract
Chronic hepatitis C is frequent and aggressive in HIV-positive patients. Identification of early predictors of response to anti-HCV therapy is needed for a lower rate of response and higher discontinuations, compared to HCV mono-infected subjects. The aim of our study was to evaluate the predictive value of virological response (VR) at week 4-8-12 of Pegylated interferon alpha-2b (PEG-IFN) plus ribavirin (RBV) on sustained virological response (SVR) in HIV-HCV co-infected patients. 100 patients were treated with PEG-IFN (1.5 mcg/Kg/w) plus RBV ( > /=10.6 mg/kg/d) and randomized for 24-48 or 48-72 weeks, respectively for genotype 2-3 and 1-4, in case of response (HCV-RNA PCR negativity) at the end of standard therapy (24 weeks for genotype 2-3, 48 weeks for genotype 1-4). Transcription-Mediated Amplification (TMA) assay for HCV-RNA was also applied. 27 patients reached end-of-treatment response (9 genotype 1-4, 18 genotype 2-3), 21 achieved SVR (8 genotype 1-4, 13 genotype 2-3). 35 patients dropped, 15 due to side-effects. SVR was statistically related to lower baseline HCV-RNA and to VR at week 4-8-12, with PPV 64%, 53% and 58%, and NPV 81%, 96% and 88%, respectively. In 27 patients, TMA was performed and confirmed standard PCR, except in two cases of relapse, who were PCR negative but TMA positive at week-12. In conclusion, VR at week 8 showed the highest NPV on SVR (96%). The study of viral kinetics requires further investigations in HIV-positive patients to guarantee a cost-effective therapy and to guide individually the duration of treatment. In this setting, TMA might be useful.
Keywords: HIV, HCV, PEG-interferon/ribavirin, viral kinetics
Current HIV Research
Title: Predictability of Sustained Virological Response to Pegylated Interferon Alpha-2b Plus Ribavirin Therapy by Week-8 Viral Response in HIVPositive Patients with Chronic Hepatitis C Virus Infection
Volume: 7 Issue: 4
Author(s): E. Angeli, A. Mainini, A. Cargnel, C. Uberti-Foppa, A. Orani, R. Carbone, M. Andreoni, M. Schiavini, R. Giorgi, G. Rizzardini and G. Gubertini
Affiliation:
Keywords: HIV, HCV, PEG-interferon/ribavirin, viral kinetics
Abstract: Chronic hepatitis C is frequent and aggressive in HIV-positive patients. Identification of early predictors of response to anti-HCV therapy is needed for a lower rate of response and higher discontinuations, compared to HCV mono-infected subjects. The aim of our study was to evaluate the predictive value of virological response (VR) at week 4-8-12 of Pegylated interferon alpha-2b (PEG-IFN) plus ribavirin (RBV) on sustained virological response (SVR) in HIV-HCV co-infected patients. 100 patients were treated with PEG-IFN (1.5 mcg/Kg/w) plus RBV ( > /=10.6 mg/kg/d) and randomized for 24-48 or 48-72 weeks, respectively for genotype 2-3 and 1-4, in case of response (HCV-RNA PCR negativity) at the end of standard therapy (24 weeks for genotype 2-3, 48 weeks for genotype 1-4). Transcription-Mediated Amplification (TMA) assay for HCV-RNA was also applied. 27 patients reached end-of-treatment response (9 genotype 1-4, 18 genotype 2-3), 21 achieved SVR (8 genotype 1-4, 13 genotype 2-3). 35 patients dropped, 15 due to side-effects. SVR was statistically related to lower baseline HCV-RNA and to VR at week 4-8-12, with PPV 64%, 53% and 58%, and NPV 81%, 96% and 88%, respectively. In 27 patients, TMA was performed and confirmed standard PCR, except in two cases of relapse, who were PCR negative but TMA positive at week-12. In conclusion, VR at week 8 showed the highest NPV on SVR (96%). The study of viral kinetics requires further investigations in HIV-positive patients to guarantee a cost-effective therapy and to guide individually the duration of treatment. In this setting, TMA might be useful.
Export Options
About this article
Cite this article as:
Angeli E., Mainini A., Cargnel A., Uberti-Foppa C., Orani A., Carbone R., Andreoni M., Schiavini M., Giorgi R., Rizzardini G. and Gubertini G., Predictability of Sustained Virological Response to Pegylated Interferon Alpha-2b Plus Ribavirin Therapy by Week-8 Viral Response in HIVPositive Patients with Chronic Hepatitis C Virus Infection, Current HIV Research 2009; 7 (4) . https://dx.doi.org/10.2174/157016209788680507
DOI https://dx.doi.org/10.2174/157016209788680507 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
HIV Vaccine Development.
The development of a safe and effective vaccine that impedes HIV-1 transmission and/or limits the severity of infection remains a public health priority. The HIV-1/AIDS pandemic continues to have a disproportionate impact on vulnerable and under-served communities in the USA and globally. In the USA, minority communities that have relatively ...read more
Lymphomas in People Living with HIV (PLWH)
In the era of combined antiretroviral therapy (cART), the incidence of lymphoma among people living with HIV (PLWH) surpassed Kaposi's sarcoma in 2011, becoming the most common AIDS-defining malignancy. The annual incidence rate ranges approximately from 100 to 300 per 100,000 individuals with HIV infection as the population denominator, which ...read more

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Hydrogen Sulfide in Inflammation: Friend or Foe?
Inflammation & Allergy - Drug Targets (Discontinued) Leuckart Synthesis and Pharmacological Assessment of Novel Acetamide Derivatives
Anti-Cancer Agents in Medicinal Chemistry Antimicrobial Peptides from Animals: Focus on Drug Discovery
Letters in Drug Design & Discovery Is there a Relationship between Endothelial Dysfunction of the Brachial Artery, Carotid Intima-Media Thickness and Soluble Receptors of Tumor Necrosis Factor-Alpha?
Vascular Disease Prevention (Discontinued) Pre-Admission Beta-Blocker Therapy and Outcomes of Coronavirus Disease 2019 (COVID-19): A Systematic Review, Meta-Analysis, and Meta-Regression
Cardiovascular & Hematological Disorders-Drug Targets Significance of Vitamin Supplementation in Reducing the Severity of COVID-19
Mini-Reviews in Medicinal Chemistry Malnutrition could Predict 3-month Functional Prognosis in Mild Stroke Patients: Findings from a Nationwide Stroke Registry
Current Neurovascular Research Psoriasis in Children: A Review
Current Pediatric Reviews Herb-Drug Interactions and Mechanistic and Clinical Considerations
Current Drug Metabolism Impact of Oral 1,25-Dihydroxy Vitamin D (Calcitriol) Replacement Therapy on Coronary Artery Risk Factors in Type 2 Diabetic Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets Trajectories of Age-Related Cognitive Decline and Potential Associated Factors of Cognitive Function in Senior Citizens of Beijing
Current Alzheimer Research Iron Chelators for the Treatment of Cancer
Current Medicinal Chemistry Abstracts from Speakers
Cardiovascular & Hematological Disorders-Drug Targets Catheter Ablation of Lone Atrial Fibrillation
Current Pharmaceutical Design Statins and Type 2 Diabetes Mellitus: An Update After 1 Year
Current Pharmaceutical Design The Role of Nutrition During the COVID-19 Pandemic: What We Know
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial from Editor-in-Chief. Postoperative Pulmonary Complications and the Importance of the Preoperative Evaluation
Current Respiratory Medicine Reviews Pediatrics for Disability: A Comprehensive Approach to Children with Syndromic Psychomotor Delay
Current Pediatric Reviews Liver-Related Factors Associated with Low Vitamin D Levels in HIV and HIV/HCV Coinfected Patients and Comparison to General Population
Current HIV Research